{"id":58985,"date":"2024-09-03T00:05:16","date_gmt":"2024-09-03T00:05:16","guid":{"rendered":"https:\/\/english.saigonbiz.com.vn\/2024\/09\/03\/praxis-precision-medicines-to-announce-topline-data-from-the-phase-2-embold-study-of-relutrigine-prax-562-in-scn2a-and-scn8a-developmental-and-epileptic-encephalopathies-on-september-3-2024\/"},"modified":"2024-09-03T00:05:16","modified_gmt":"2024-09-03T00:05:16","slug":"praxis-precision-medicines-to-announce-topline-data-from-the-phase-2-embold-study-of-relutrigine-prax-562-in-scn2a-and-scn8a-developmental-and-epileptic-encephalopathies-on-september-3-2024","status":"publish","type":"post","link":"https:\/\/english.saigonbiz.com\/vn\/praxis-precision-medicines-to-announce-topline-data-from-the-phase-2-embold-study-of-relutrigine-prax-562-in-scn2a-and-scn8a-developmental-and-epileptic-encephalopathies-on-september-3-2024\/","title":{"rendered":"Praxis Precision Medicines to Announce Topline Data from the Phase 2 EMBOLD Study of Relutrigine (PRAX-562) in SCN2A and SCN8A Developmental and Epileptic Encephalopathies on September 3, 2024"},"content":{"rendered":"
\n

BOSTON, Mass., Sept. 02, 2024 (GLOBE NEWSWIRE) — Praxis Precision Medicines<\/u><\/a>, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that it will share the topline results from the Phase 2 EMBOLD study of relutrigine (PRAX-562) in SCN2A and SCN8A Developmental and Epileptic Encephalopathies (DEEs) on Tuesday, September 3, 2024, prior to market open. Following the announcement, the Company will host a conference call and webcast presentation at 8:00 a.m. ET to discuss the trial results.<\/p>\n

Conference Call and Webcast Presentation<\/strong>
Date and Time: Tuesday, September 3, 2024 at 8:00 a.m. ET
Webcast: LINK<\/a><\/p>\n

A replay of the presentation will be posted, when available, to Praxis\u2019 website on the \u201cEvents and Presentations<\/a>\u201d page under the investor section of the website<\/a>.<\/p>\n

About Praxis<\/strong>\u202f\u00a0
Praxis Precision Medicines is a clinical-stage biopharmaceutical company translating insights from genetic epilepsies into the development of therapies for CNS disorders characterized by neuronal excitation-inhibition imbalance. Praxis is applying genetic insights to the discovery and development of therapies for rare and more prevalent neurological disorders through our proprietary small molecule platform, Cerebrum™, and antisense oligonucleotide (ASO) platform, Solidus™, using our understanding of shared biological targets and circuits in the brain. Praxis has established a diversified, multimodal CNS portfolio including multiple programs across movement disorders and epilepsy, with four clinical-stage product candidates. For more information, please visit\u00a0www.praxismedicines.com<\/a>\u00a0and follow us on\u00a0Facebook<\/a>,\u00a0LinkedIn<\/a>\u00a0and\u00a0Twitter\/X<\/a>.<\/p>\n

CONTACT: Investor Contact:\u00a0\r\nPraxis Precision Medicines\u00a0\r\ninvestors@praxismedicines.com\u00a0\r\n857-702-9452\u00a0\r\n\u00a0\r\nMedia Contact:\r\nDan Ferry\r\nLife Science Advisors\r\nDaniel@lifesciadvisors.com\r\n617-430-7576<\/pre>\n
<\/div>\n","protected":false},"excerpt":{"rendered":"
BOSTON, Mass., Sept. 02, 2024 (GLOBE NEWSWIRE) — Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that it will share the topline results from the Phase 2 EMBOLD study of relutrigine (PRAX-562) […]\n","protected":false},"author":1,"featured_media":58986,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-58985","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-pr-newswire"],"yoast_head":"\nPraxis Precision Medicines to Announce Topline Data from the Phase 2 EMBOLD Study of Relutrigine (PRAX-562) in SCN2A and SCN8A Developmental and Epileptic Encephalopathies on September 3, 2024 - Biz and Live in Saigon<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/english.saigonbiz.com\/vn\/praxis-precision-medicines-to-announce-topline-data-from-the-phase-2-embold-study-of-relutrigine-prax-562-in-scn2a-and-scn8a-developmental-and-epileptic-encephalopathies-on-september-3-2024\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Praxis Precision Medicines to Announce Topline Data from the Phase 2 EMBOLD Study of Relutrigine (PRAX-562) in SCN2A and SCN8A Developmental and Epileptic Encephalopathies on September 3, 2024\" \/>\n<meta property=\"og:description\" content=\"BOSTON, Mass., Sept. 02, 2024 (GLOBE NEWSWIRE) — Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company tra\" \/>\n<meta property=\"og:url\" content=\"https:\/\/english.saigonbiz.com\/vn\/praxis-precision-medicines-to-announce-topline-data-from-the-phase-2-embold-study-of-relutrigine-prax-562-in-scn2a-and-scn8a-developmental-and-epileptic-encephalopathies-on-september-3-2024\/\" \/>\n<meta property=\"og:site_name\" content=\"Biz and Live in Saigon\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/SaigonbizGroup\" \/>\n<meta property=\"article:published_time\" content=\"2024-09-03T00:05:16+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2024\/09\/Praxis-Precision-Medicines-Inc.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1\" \/>\n\t<meta property=\"og:image:height\" content=\"1\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"admin\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"admin\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/praxis-precision-medicines-to-announce-topline-data-from-the-phase-2-embold-study-of-relutrigine-prax-562-in-scn2a-and-scn8a-developmental-and-epileptic-encephalopathies-on-september-3-2024\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/praxis-precision-medicines-to-announce-topline-data-from-the-phase-2-embold-study-of-relutrigine-prax-562-in-scn2a-and-scn8a-developmental-and-epileptic-encephalopathies-on-september-3-2024\/\"},\"author\":{\"name\":\"admin\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/267b348e6cf32a66aab33637c2d399a6\"},\"headline\":\"Praxis Precision Medicines to Announce Topline Data from the Phase 2 EMBOLD Study of Relutrigine (PRAX-562) in SCN2A and SCN8A Developmental and Epileptic Encephalopathies on September 3, 2024\",\"datePublished\":\"2024-09-03T00:05:16+00:00\",\"dateModified\":\"2024-09-03T00:05:16+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/praxis-precision-medicines-to-announce-topline-data-from-the-phase-2-embold-study-of-relutrigine-prax-562-in-scn2a-and-scn8a-developmental-and-epileptic-encephalopathies-on-september-3-2024\/\"},\"wordCount\":272,\"publisher\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#organization\"},\"articleSection\":[\"Pr Newswire\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/praxis-precision-medicines-to-announce-topline-data-from-the-phase-2-embold-study-of-relutrigine-prax-562-in-scn2a-and-scn8a-developmental-and-epileptic-encephalopathies-on-september-3-2024\/\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/praxis-precision-medicines-to-announce-topline-data-from-the-phase-2-embold-study-of-relutrigine-prax-562-in-scn2a-and-scn8a-developmental-and-epileptic-encephalopathies-on-september-3-2024\/\",\"name\":\"Praxis Precision Medicines to Announce Topline Data from the Phase 2 EMBOLD Study of Relutrigine (PRAX-562) in SCN2A and SCN8A Developmental and Epileptic Encephalopathies on September 3, 2024 - Biz and Live in Saigon\",\"isPartOf\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#website\"},\"datePublished\":\"2024-09-03T00:05:16+00:00\",\"dateModified\":\"2024-09-03T00:05:16+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/praxis-precision-medicines-to-announce-topline-data-from-the-phase-2-embold-study-of-relutrigine-prax-562-in-scn2a-and-scn8a-developmental-and-epileptic-encephalopathies-on-september-3-2024\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/english.saigonbiz.com\/vn\/praxis-precision-medicines-to-announce-topline-data-from-the-phase-2-embold-study-of-relutrigine-prax-562-in-scn2a-and-scn8a-developmental-and-epileptic-encephalopathies-on-september-3-2024\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/praxis-precision-medicines-to-announce-topline-data-from-the-phase-2-embold-study-of-relutrigine-prax-562-in-scn2a-and-scn8a-developmental-and-epileptic-encephalopathies-on-september-3-2024\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/english.saigonbiz.com\/vn\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Praxis Precision Medicines to Announce Topline Data from the Phase 2 EMBOLD Study of Relutrigine (PRAX-562) in SCN2A and SCN8A Developmental and Epileptic Encephalopathies on September 3, 2024\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#website\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/\",\"name\":\"Biz and Live in Saigon\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/english.saigonbiz.com\/vn\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#organization\",\"name\":\"SaigonBiz Media\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/cropped-c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview.png\",\"contentUrl\":\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/cropped-c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview.png\",\"width\":512,\"height\":512,\"caption\":\"SaigonBiz Media\"},\"image\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/SaigonbizGroup\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/267b348e6cf32a66aab33637c2d399a6\",\"name\":\"admin\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview-2_uwp_avatar_thumb.png\",\"contentUrl\":\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview-2_uwp_avatar_thumb.png\",\"caption\":\"admin\"},\"sameAs\":[\"https:\/\/english.saigonbiz.com\/vn\"],\"url\":\"https:\/\/english.saigonbiz.com\/vn\/profile\/admin\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Praxis Precision Medicines to Announce Topline Data from the Phase 2 EMBOLD Study of Relutrigine (PRAX-562) in SCN2A and SCN8A Developmental and Epileptic Encephalopathies on September 3, 2024 - Biz and Live in Saigon","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/english.saigonbiz.com\/vn\/praxis-precision-medicines-to-announce-topline-data-from-the-phase-2-embold-study-of-relutrigine-prax-562-in-scn2a-and-scn8a-developmental-and-epileptic-encephalopathies-on-september-3-2024\/","og_locale":"en_US","og_type":"article","og_title":"Praxis Precision Medicines to Announce Topline Data from the Phase 2 EMBOLD Study of Relutrigine (PRAX-562) in SCN2A and SCN8A Developmental and Epileptic Encephalopathies on September 3, 2024","og_description":"BOSTON, Mass., Sept. 02, 2024 (GLOBE NEWSWIRE) — Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company tra","og_url":"https:\/\/english.saigonbiz.com\/vn\/praxis-precision-medicines-to-announce-topline-data-from-the-phase-2-embold-study-of-relutrigine-prax-562-in-scn2a-and-scn8a-developmental-and-epileptic-encephalopathies-on-september-3-2024\/","og_site_name":"Biz and Live in Saigon","article_publisher":"https:\/\/www.facebook.com\/SaigonbizGroup","article_published_time":"2024-09-03T00:05:16+00:00","og_image":[{"width":1,"height":1,"url":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2024\/09\/Praxis-Precision-Medicines-Inc.png","type":"image\/png"}],"author":"admin","twitter_card":"summary_large_image","twitter_misc":{"Written by":"admin","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/english.saigonbiz.com\/vn\/praxis-precision-medicines-to-announce-topline-data-from-the-phase-2-embold-study-of-relutrigine-prax-562-in-scn2a-and-scn8a-developmental-and-epileptic-encephalopathies-on-september-3-2024\/#article","isPartOf":{"@id":"https:\/\/english.saigonbiz.com\/vn\/praxis-precision-medicines-to-announce-topline-data-from-the-phase-2-embold-study-of-relutrigine-prax-562-in-scn2a-and-scn8a-developmental-and-epileptic-encephalopathies-on-september-3-2024\/"},"author":{"name":"admin","@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/267b348e6cf32a66aab33637c2d399a6"},"headline":"Praxis Precision Medicines to Announce Topline Data from the Phase 2 EMBOLD Study of Relutrigine (PRAX-562) in SCN2A and SCN8A Developmental and Epileptic Encephalopathies on September 3, 2024","datePublished":"2024-09-03T00:05:16+00:00","dateModified":"2024-09-03T00:05:16+00:00","mainEntityOfPage":{"@id":"https:\/\/english.saigonbiz.com\/vn\/praxis-precision-medicines-to-announce-topline-data-from-the-phase-2-embold-study-of-relutrigine-prax-562-in-scn2a-and-scn8a-developmental-and-epileptic-encephalopathies-on-september-3-2024\/"},"wordCount":272,"publisher":{"@id":"https:\/\/english.saigonbiz.com\/vn\/#organization"},"articleSection":["Pr Newswire"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/english.saigonbiz.com\/vn\/praxis-precision-medicines-to-announce-topline-data-from-the-phase-2-embold-study-of-relutrigine-prax-562-in-scn2a-and-scn8a-developmental-and-epileptic-encephalopathies-on-september-3-2024\/","url":"https:\/\/english.saigonbiz.com\/vn\/praxis-precision-medicines-to-announce-topline-data-from-the-phase-2-embold-study-of-relutrigine-prax-562-in-scn2a-and-scn8a-developmental-and-epileptic-encephalopathies-on-september-3-2024\/","name":"Praxis Precision Medicines to Announce Topline Data from the Phase 2 EMBOLD Study of Relutrigine (PRAX-562) in SCN2A and SCN8A Developmental and Epileptic Encephalopathies on September 3, 2024 - Biz and Live in Saigon","isPartOf":{"@id":"https:\/\/english.saigonbiz.com\/vn\/#website"},"datePublished":"2024-09-03T00:05:16+00:00","dateModified":"2024-09-03T00:05:16+00:00","breadcrumb":{"@id":"https:\/\/english.saigonbiz.com\/vn\/praxis-precision-medicines-to-announce-topline-data-from-the-phase-2-embold-study-of-relutrigine-prax-562-in-scn2a-and-scn8a-developmental-and-epileptic-encephalopathies-on-september-3-2024\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/english.saigonbiz.com\/vn\/praxis-precision-medicines-to-announce-topline-data-from-the-phase-2-embold-study-of-relutrigine-prax-562-in-scn2a-and-scn8a-developmental-and-epileptic-encephalopathies-on-september-3-2024\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/english.saigonbiz.com\/vn\/praxis-precision-medicines-to-announce-topline-data-from-the-phase-2-embold-study-of-relutrigine-prax-562-in-scn2a-and-scn8a-developmental-and-epileptic-encephalopathies-on-september-3-2024\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/english.saigonbiz.com\/vn\/"},{"@type":"ListItem","position":2,"name":"Praxis Precision Medicines to Announce Topline Data from the Phase 2 EMBOLD Study of Relutrigine (PRAX-562) in SCN2A and SCN8A Developmental and Epileptic Encephalopathies on September 3, 2024"}]},{"@type":"WebSite","@id":"https:\/\/english.saigonbiz.com\/vn\/#website","url":"https:\/\/english.saigonbiz.com\/vn\/","name":"Biz and Live in Saigon","description":"","publisher":{"@id":"https:\/\/english.saigonbiz.com\/vn\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/english.saigonbiz.com\/vn\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/english.saigonbiz.com\/vn\/#organization","name":"SaigonBiz Media","url":"https:\/\/english.saigonbiz.com\/vn\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/logo\/image\/","url":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/cropped-c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview.png","contentUrl":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/cropped-c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview.png","width":512,"height":512,"caption":"SaigonBiz Media"},"image":{"@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/SaigonbizGroup"]},{"@type":"Person","@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/267b348e6cf32a66aab33637c2d399a6","name":"admin","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/image\/","url":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview-2_uwp_avatar_thumb.png","contentUrl":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview-2_uwp_avatar_thumb.png","caption":"admin"},"sameAs":["https:\/\/english.saigonbiz.com\/vn"],"url":"https:\/\/english.saigonbiz.com\/vn\/profile\/admin\/"}]}},"_links":{"self":[{"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/posts\/58985","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/comments?post=58985"}],"version-history":[{"count":0,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/posts\/58985\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/media\/58986"}],"wp:attachment":[{"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/media?parent=58985"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/categories?post=58985"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/tags?post=58985"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}